Why is the CEO of Percheron Therapeutics (ASX:PER) stepping down?

The outgoing CEO of Percheron Therapeutics (ASX:PER), Dr James Garner, is resigning to take up a new professional opportunity overseas. The company stated that Dr Garner will transition to a Non-Executive Director role on 1 September 2026 to ensure continuity.

Who is the new CEO of Percheron Therapeutics (ASX:PER) and how will he be paid?

Percheron Therapeutics (ASX:PER) appointed Dr Michael Baker as its new Managing Director and CEO effective Oct. 5. The company noted his remuneration package features a reduced cash component, which is offset by an equity component tied to share price and tenure milestones.

How is the board of Percheron Therapeutics (ASX:PER) managing the leadership transition?

Percheron Therapeutics (ASX:PER) stated that Dr Garner will remain in his current position until Aug. 31 to facilitate an orderly handover. All existing Non-Executive Directors and other management team members will remain in their current roles.

What is the clinical trial timeline for Percheron Therapeutics (ASX:PER)?

Percheron Therapeutics (ASX:PER) forecasts that it remains on track to commence a new clinical trial for its lead oncology candidate, HMBD-002, during the second half of calendar year 2026. This target aligns with the company's previously issued guidance.

How did the stock of Percheron Therapeutics (ASX:PER) react to the leadership change?

The share price of Percheron Therapeutics (ASX:PER) remained completely unchanged at A$0.003 following the announcement of the executive leadership succession. The business also recently raised $2.2 million via an entitlement offer to fund its upcoming clinical research activities.

Health

Image for illustrative purposes only. Not a real photo.

Percheron Therapeutics appoints new CEO

Written by Brie CarterPublished Aug 9, 2026, 11:38 PM

Percheron Therapeutics announced Dr Michael Baker will replace Dr James Garner as CEO on Oct. 5.
The company's stock remained completely unchanged at $0.003 following the executive leadership succession announcement.
The leadership transition is intended to maintain continuity as the business prepares for upcoming clinical trials.

Percheron Therapeutics (ASX:PER) appointed Dr Michael Baker as CEO effective Oct. 5 to guide future trials.

Dr James Garner will step down on Aug. 31 after leading the business since August 2023.

“We wish him well in his new role,” said Percheron Therapeutics Chair Dr Charmaine Gittleson.

The company stated it remains on track to commence a new HMBD-002 clinical trial during late 2026.

Following the announcement, the Percheron share price was unchanged at $0.003.

Percheron previously reported completing a new drug substance manufacturing batch for its lead oncology candidate HMBD-002.

The business recently raised $2.2 million via an entitlement offer to fund upcoming clinical research activities.

Percheron Therapeutics appoints new CEO

Frequently asked questions

Assets related to this article